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45Background: The objective of this HERO study was to assess the number of new cancer patients that will
require at least one course of radiotherapy by 2025.
Methods: European cancer incidence data by tumor site and country for 2012 and 2025 was extracted
from the GLOBOCAN database. The projection of the number of new cases took into account demographic
factors (age and size of the population). Population based stages at diagnosis were taken from four
European countries. Incidence and stage data were introduced in the Australian Collaboration for
Cancer Outcomes Research and Evaluation (CCORE) model.
Results: Among the different tumor sites, the highest expected relative increase by 2025 in treatment
courses was prostate cancer (24%) while lymphoma (13%), head and neck (12%) and breast cancer
(10%) were below the average. Based on the projected cancer distributions in 2025, a 16% expected
increase in the number of radiotherapy treatment courses was estimated. This increase varied across
European countries from less than 5% to more than 30%.
Conclusion: With the already existing disparity in radiotherapy resources in mind, the data provided here
should act as a leverage point to raise awareness among European health policy makers of the need for
investment in radiotherapy.
 2016 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2016) xxx–xxx4665
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81The number of newly-diagnosed cancer patients that would
require radiotherapy treatment using an evidence-based approach
was estimated for all European countries for the year 2012 within
the framework of the ESTRO-HERO (Health Economics in Radiation
Oncology) project [1]. The estimate was based on optimal utiliza-
tion of radiation oncology according to the CCORE methodological
approach [2], using incidence data for European countries as esti-
mated by the International Agency for Research on Cancer (IARC)
[3,4], and combined with data on stage at diagnosis from four
population-based cancer registries (The Netherlands, Slovenia,
Grater Poland region of Poland, and Belgium) available in the cat-
egories required [5].
This estimation provides a useful tool for planning the required
equipment and staff needs. One of the critical results was the
observed gap between the optimal utilization and the actual use
of radiotherapy, with most countries covering less than 80% of
the evidence-based demand for treatment compared with actualuse [1]. This evidence could be immediately applied to improve
cancer control planning with respect to placing the necessary
investments required to cope with the demand of cancer patients.
Long-term planning is required for radiotherapy facilities as
well as for the staff needed, due to the significant interval between
the time of making decisions for facility investments and training
of personnel and the time when they become a clinical reality. A
forecast of the anticipated changes in terms of new cancer patients
that would need radiotherapy in the short- to medium-term time
horizon seems rational, and fits within the objectives of the
ESTRO-HERO project.
The aim of this paper is then to assess the number of new can-
cer patients by tumor site that will require radiotherapy in 2025 as
compared to the 2012 data, using the national cancer incidence
estimates based on data from the population-based cancer reg-
istries available in each European country together with projec-
tions carried out by IARC in GLOBOCAN [6].nalysis.
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20 February 2016Materials and methods
European country-specific cancer incidence by tumor type was
extracted from the GLOBOCAN database [4] for the year 2012. The
detailed description of the data and the methods used to compute
these estimates is given elsewhere [3]. To summarize, statistical
models were developed to predict incidence rates for the year
2012 from recent trends, wherever possible. The country, sex,
and site estimated incidence rates in 2012 were then applied to
the corresponding population estimates to obtain the estimated
numbers of new cancers in each European country in 2012. Projec-
tions for the year 2025 were computed using the facility available
at the GLOBOCAN website [4]. The projected numbers of new can-
cer cases have been derived by applying the age-specific incidence
rates estimated for 2012 to the corresponding forecast population
in 2025. Therefore, the projected incident cases for 2025 took into
account the demographic changes (age structure and size), but not
the potential impact of the changes in risk factors.
Tumor sites included in the analysis were as follows: bladder,
brain, breast, cervix, colon, gallbladder, head and neck (lip, oral
cavity, larynx, oropharynx, hypopharynx and nasopharynx), kid-
ney, leukemia, lung, lymphoma (including Hodgkin and non-
Hodgkin lymphoma), melanoma, multiple myeloma, esophagus,
ovary, pancreas, prostate, rectum, stomach, testis and corpus
uteri). It has been necessary to adapt the categories provided by
GLOBOCAN to fulfill the requirements of the radiotherapy
evidence-based Optimal Utilization Proportion (OUP) [2]. ‘‘Colon
and rectum” cancer was partitioned into colon and rectal cancers,
‘‘lip and oral cavity” into lip and oral cavity and the category ‘‘other
pharynx” into oropharynx and hypopharynx. In order to do this, we
extracted data from population-based cancer registries available in
the last volume of Cancer Incidence in Five Continents [7] for as
many European countries as possible and computed proportions
of each individual category. When no data were available in a par-
ticular country (such as Albania, Macedonia or Luxembourg), the
data from a neighboring country was used. The same proportions
were used in the 2012 and 2025 estimates.
OUP of radiotherapy by tumor site was obtained from the
Australian Collaboration for Cancer Outcomes Research and Evalua-
tion (CCORE) review [2], which provided radiotherapy indications
for all tumor sites according to the relevant evidence-based clinical
guidelinesby tumor site and stage at diagnosis, updated to 2012. The
stage at diagnosis originally used in the CCORE was from the Aus-
tralian cancer registry. Four different European cancer registries
provided data fitted to the CCORE decision trees structure (Slovenia,
Grater Poland region of Poland, Belgium and The Netherlands) in
order to estimate the OUP using a range of stage at diagnosis from
distinct European countries. Themethodological details of this anal-
ysis have been provided elsewhere [5]. The same OUPswere used in
the 2012 and 2025 estimates. For the correct interpretation of the
OUPs it is necessary to know that each patient is counted only once,
even if he or she subsequently required further treatment for the
particular cancer. Brachytherapy treatments were not considered.196
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About 4 millionnewcancer patients are predicted in 2025 in Eur-
opebasedondemographic changes. This represents a 15.9% increase
in the absolute number of cases compared to the 3.4 million diag-
nosed in 2012, assuming overall cancer rates remain unchanged
(Table 1). Using the lowest OUP estimated for each country, the
absolute numberof patients thatwouldhave an indication for radio-
therapy at least once during the course of the diseasewould increase
from1,700,000patients approximately in2012 to2,000,000 in2025.
This represents a 16.1% increase over the entire period.Please cite this article in press as: Borras JM et al. How many new cancer patien
Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.02.016This increase in the number of expected cases is not distributed
evenly across European countries (Table 1 and Fig. 1). Eastern
European countries exhibited, broadly speaking, the lowest per-
centile increases, with Bulgaria, Ukraine, Latvia and Lithuania
expecting decreases in the number of new cancer cases, while
the incidence burden in many of the rest of Eastern countries is
predicted to increase by less than 10%. The exceptions were Poland,
the Czech Republic and Slovakia with increases of around 20% or
above. However, when the focus is on the absolute in numbers,
as shown in Fig. 2, it is clear that the greater increases are esti-
mated in the most densely populated countries.
South-Eastern European countries showed a diversity of esti-
mated changes in the number of patients, from a relative decrease
in Bulgaria (0.8%) to an increase of 33.4% in Albania. The highest
relative increases were observed among small countries with no
clear geographic pattern (Iceland, Ireland and Cyprus) with
increases above 35%, while the incidence rises in more populated
countries such as The Netherlands, Switzerland and Norway were
between 25% and 31%. The countries of Western Europe, including
France, Germany, Italy, Spain or the UK, with the highest volume of
population, exhibited increases in the number of new cases from
2012 to 2025 by between 15% and 25%.
Relative changes by tumor site and for all countries combined
are presented in Table 2. It is worth noting that prostate cancer
produced the highest increase over the period considered with a
24.4% rise followed by bladder cancer and multiple myeloma,
while female breast cancer, lymphomas and head and neck cancer
were below average. Importantly, cervical cancer only increased by
1.1% while the numbers of patients with a radiotherapy indication
for cancer of the testis declined.
The tumors that make up the highest percentage of patients in a
radiotherapy department, namely breast, rectum, head and neck,
lung and prostate cancers are shown in Table 3 for each European
country with their absolute and relative increase. Some relative
increases are noteworthy and deserve close analysis at national
level. For instance, countries such as Spain, The Netherlands or
the Czech Republic show an increase higher than 25% for rectal
cancer patients with a radiotherapy indication, while Belgium,
UK or Denmark have an estimated increase above 20%. Also, the
estimated increase for prostate or lung cancer is very important
in many western European countries, higher than 20%; while the
observed increases for breast cancer patients are moderate in
comparison.
Fig. 3 provides a visual representation of the cancer types with
the highest absolute number of radiotherapy indications, projected
for the 2025. Interestingly, in several countries bladder cancer
ranks among the most frequent cases according to the evidence-
based indications, due to its high incidence in these countries. A
similar observation can be made for lymphoma (estimates by
country for all tumor types can be consulted in the web-based
Supplementary material).
Discussion
Projections of the incidence of cancer are helpful in assessing
the future burden of cancer and in order to establish appropriate
cancer control plans to cope with the challenge posed by a growing
number of cancer patients. The projections carried out in GLOBO-
CAN by IARC, combined with the evidence-based data on radio-
therapy indications offer a unique opportunity to undertake
long-term radiotherapy resource planning. The obtained data, by
tumor site and by country within Europe, give guidance for making
the necessary investments in services and equipment and for
setting-up training of dedicated personnel, necessary actions to
adequately manage the increased radiotherapy demands expected
in the near future.ts in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.
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Table 1
Cancer cases with an evidence based indication for external radiotherapy 2012 and 2025.
Country Total cancers (n)[a] OUP (%)[b] Optimal radiotherapy courses (n)
2012 2025 % Var. 2012–25
2012 2025 Min. Max. OUP min. OUP max. OUP min. OUP max. OUP min./max.
Albania 7143 9,532 52.6 54.3 3758 3879 5014 5177 33.4
Austria 41,117 50,167 49 50.3 20,155 20,698 24,591 25,253 22
Belarus 32,422 33,649 48.5 50.3 15,738 16,293 16,333 16,909 3.8
Belgium 65,345 78,488 53.2 54.8 34,792 35,799 41,790 43,000 20.1
Bosnia Herzegovina 9911 11,538 52.8 54.4 5236 5395 6096 6280 16.4
Bulgaria 32,053 31,792 51.3 53 16,434 16,977 16,301 16,838 0.8
Croatia 22,890 25,143 51.2 52.7 11,717 12,055 12,870 13,242 9.8
Cyprus 3438 4724 51 52.3 1753 1799 2409 2471 37.4
Czech Republic 57,627 70,553 48.5 50.2 27,943 28,945 34,211 35,437 22.4
Denmark 36,119 43,557 52.8 54.3 19,064 19,600 22,990 23,636 20.6
Estonia 6117 6310 49.1 50.8 3004 3104 3099 3202 3.2
Finland 28,428 34,460 52.1 53.4 14,810 15,189 17,952 18,412 21.2
France 3,71,676 4,46,670 51.9 53.3 1,92,769 1,98,107 2,31,665 2,38,079 20.2
Germany 4,93,780 5,68,892 50.1 51.6 2,47,419 2,54,735 2,85,056 2,93,485 15.2
Greece 40,971 46,621 52.5 54.2 21,523 22,213 24,491 25,276 13.8
Hungary 50,475 54,051 50.3 51.9 25,412 26,209 27,212 28,065 7.1
Iceland 1449 1997 50.7 51.8 734 750 1,012 1,034 37.8
Ireland 20,808 28,432 51.5 52.9 10,714 11,017 14,640 15,053 36.6
Italy 3,54,456 4,11,515 48.2 49.3 1,70,821 1,74,764 1,98,320 2,02,897 16.1
Latvia 10,347 9567 49.9 51.4 5166 5315 4777 4914 7.5
Lithuania 14,520 13,514 49.9 51.5 7244 7483 6742 6965 6.9
Luxembourg 2476 3231 50.6 52 1252 1289 1634 1682 30.5
Macedonia 7330 9097 52.6 54.3 3856 3981 4786 4941 24.1
Malta 1902 2563 51.9 53.3 988 1014 1331 1367 34.8
Moldova 9894 10,371 50.2 52.1 4969 5151 5208 5399 4.8
Montenegro 2115 2341 52.2 53.8 1105 1139 1223 1260 10.7
Norway 28,214 36,334 49 50.5 13,818 14,248 17,795 18,349 28.8
Poland 1,52,216 1,81,072 52 53.4 79,139 81,294 94,142 96,705 19
Portugal 49,174 57,436 49.7 51.1 24,438 25,151 28,543 29,377 16.8
Romania 78,760 87,623 50 51.8 39,383 40,805 43,814 45,397 11.3
Russian Federation 4,58,382 4,87,682 47 48.6 2,15,507 2,22,922 2,29,282 2,37,172 6.4
Serbia 42,221 44,392 52.2 53.8 22,050 22,733 23,184 23,901 5.1
Slovakia 24,045 29,911 48.2 50.2 11,599 12,071 14,428 15,016 24.4
Slovenia 11,457 14,207 49.6 51.3 5680 5874 7044 7284 24
Spain 2,15,534 2,68,960 49.7 51.1 1,07,018 1,10,159 1,33,545 1,37,465 24.8
Sweden 50,481 59,410 51.4 52.8 25,928 26,662 30,514 31,378 17.7
Switzerland 42,046 55,088 50.6 52 21,294 21,865 27,900 28,647 31
The Netherlands 93,448 1,17,999 52.3 53.9 48,886 50,324 61,729 63,546 26.3
Ukraine 1,40,999 1,40,928 50.2 52.1 70,811 73,403 70,775 73,366 0.1
United Kingdom 3,27,812 3,98,471 53 54.4 1,73,612 1,78,405 2,11,034 2,16,860 21.6
Global 34,39,598 39,88,288 50.2 51.7 17,27,538 17,78,816 20,05,480 20,64,739 16.1
[a] All cancers excl. non-melanoma skin cancer. Globocan 2012/2025.
[b] OUP: optimal utilization proportion.
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20 February 2016Other groups have performed similar exercises. Datta and col-
leagues made estimates of the additional number of treatment
units and personnel – radiation oncologists, medical physicists
and radiation technologists – required in 39 European countries
by 2020 [8]. Actual radiotherapy resources were obtained from
the DIRAC (Directory of Radiotherapy Centres) database; whereas
actual and future needs were computed using actual and projected
cancer incidence data from GLOBOCAN, combined with the
assumption that 62.5% of all cancer patients would require RT
(50% of new cancer patients plus 25% of these for re-irradiation)
and with required machine and staffing levels based on ESTRO-
QUARTS [9] and IAEA recommendations [10]. In contrast to their
approach, our projections are restricted to the number of cancer
patients that can be expected to benefit from radiotherapy by
2025, hence courses that should be delivered, without making
assumptions – as yet – about the resources that would be required
to make this possible. Our previously published HERO-analysis has
indeed demonstrated that the available European radiotherapy
guidelines do not sufficiently take into account the rapid technol-
ogy evolution in radiotherapy, hence in our view do not provide
sufficiently robust estimates to correctly predict the real resource
needs for each individual country [11]. With their activity-basedPlease cite this article in press as: Borras JM et al. How many new cancer patien
Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.02.016approach using time-based estimates for diverse activities within
the radiotherapy treatment process (instead of using average
throughput estimates), the Global Task Force on Radiotherapy for
Cancer Control has taken an important step in forecasting radio-
therapy resource needs for a given patient population, requiring
a certain number of radiotherapy courses [12]. The HERO-project
is now adopting a similar activity-based approach to develop a pro-
ductivity and costing model that can be tailored to the specific
needs of each European jurisdiction, based on the actual radiother-
apy needs down to the level of each cancer type, and accounting for
the evolving radiotherapy practice in terms of complexity and frac-
tionation schedules.
The effects taken into account by the methodology used in the
projections of cancer incidence are demographic (age structure
changes and population size), the major contributor to future
increasing number of new cancer cases in Europe [13]. Risk factor
changes and their potential consequences on incidence or, more
simply, trends-based approaches have however not been consid-
ered. All factors taken into account, the projection methodology
applied here could be considered conservative, assuming that
changes in age-specific rates beyond 2012 were assumed to remain
constant through 2025. The uncertainties associated with possiblets in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.
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Fig. 1. Increase in new cancer patients that would require radiotherapy by 2025 by
country (%).
Table 2
Cancer cases with an evidence based indication for external radiotherapy 2012 and
2025.
Tumor site Optimal radiotherapy courses (n)
2012 (OUP min.)[a] Increase in number of
radiotherapy courses
2025
n %
Bladder 70,679 14,842 21.0
Brain 45,717 4622 10.1
Breast 396,891 40,524 10.2
Cervix 36,384 405 1.1
Colon 9090 1740 19.1
Gall bladder 3490 667 19.1
Head and neck 108,194 13,337 12.3
Kidney 14,242 2139 15.0
Leukemia 2442 366 15.0
Lung 315,197 56,558 17.9
Lymphoma 74,852 9871 13.2
Melanoma 11,725 1340 11.4
Myeloma 17,821 3629 20.4
Esophagus 33,292 5955 17.9
Ovary 1268 124 9.8
Pancreas 40,144 7198 17.9
Prostate 243,669 59,493 24.4
Rectum 99,493 18,314 18.4
Stomach 37,185 5675 15.3
Testis 738 45 6.1
Thyroid 2365 107 4.5
Uterus 33,341 4146 12.4
[a] OUP: optimal utilization proportion.
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20 February 2016determinants in the future – the risk profile and diagnostic changes
– may be considered sufficiently high as to make reliable predic-
tions of their impact on future trends a difficult and potentially
misleading exercise [14].
The second source of data used in this study has been the OUP.
Any possible change in the evidence-base of the radiotherapy indi-
cations in the coming future, and consequently in the OUP for any
particular tumor site, will have implications for the expected num-
ber of cases for radiotherapy treatment. However, the OUP has
been quite robust when considered for all cancers together when
the update of 2012 was compared to the evaluation of the clinicalFig. 2. Optimal number of courses of radiotherapy in 2012 and estim
Please cite this article in press as: Borras JM et al. How many new cancer patien
Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.02.016guidelines up to the year 2003 [2,15]. In fact, the expansion of con-
servative approaches to organ preservation, and the increased
combination of radiotherapy and chemotherapy in tumor sites
such as cervical, rectal or lung cancer [16], related to an earlier
stage at diagnosis, will most probably expand the number of
candidates for radiotherapy. Moreover, new radiotherapy tech-
niques that involve more precision in the delivery of the dose
and less toxic effects on the surrounding tissue jointly with newated absolute increase in optimal number of courses by 2025.
ts in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.
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Table 3
Increase in the number of new cancer cases that would require radiotherapy by 2025 and relative percentage increase between 2012 and 2025 for the 5 most frequent indications.
Country Effects of OFC
inactivations
Head and neck Lung Prostate Rectum
Increase Increase Increase Increase Increase
n % n % n % n % n %
Albania 146 16.7 103 39.6 370 43.6 96 49.3 32 37.1
Austria 584 13.0 227 19.9 868 24.7 1019 29.9 248 25.8
Belarus 77 2.4 55 4.0 214 6.9 76 6.1 69 6.6
Belgium 1020 11.5 343 16.5 1401 23.4 1537 28.0 370 22.5
Bosnia Herzegovina 81 8.2 78 17.5 274 20.6 112 27.7 57 19.4
Bulgaria 125 3.7 12 1.1 0 0.0 42 3.9 20 1.7
Croatia 81 3.6 67 7.9 287 12.2 258 21.8 107 13.1
Cyprus 145 28.1 15 33.4 87 40.9 137 48.8 29 42.1
Czech Republic 815 13.9 252 15.8 1197 23.3 1275 31.8 525 26.7
Denmark 538 12.0 125 13.7 788 22.4 831 27.3 245 24.8
Estonia 12 2.1 7 4.5 27 5.5 49 8.2 8 4.4
Finland 313 8.2 73 15.1 506 26.4 836 26.6 160 25.6
France 6253 13.5 1599 13.6 5994 19.5 10,846 25.2 1994 24.2
Germany 5376 8.8 1431 9.5 6775 17.3 9161 23.0 2872 18.0
Greece 395 9.4 132 14.5 880 16.6 319 16.8 119 15.2
Hungary 184 4.2 146 5.2 494 6.9 228 12.3 201 9.6
Iceland 53 27.6 8 38.9 54 43.2 74 46.5 15 39.5
Ireland 744 30.0 146 34.0 714 40.9 905 40.9 155 40.7
Italy 4323 10.0 1303 16.3 5757 20.1 5596 21.5 1763 18.2
Latvia 92 9.4 18 6.2 55 6.1 47 5.4 12 6.4
Lithuania 75 5.9 14 3.2 68 5.7 80 9.0 23 6.4
Luxembourg 68 21.9 14 23.5 67 33.3 79 40.2 26 31.9
Macedonia 169 17.2 48 23.0 266 27.3 96 37.6 44 27.7
Malta 50 18.8 23 37.6 67 48.1 63 53.5 19 37.7
Moldova 43 4.5 6 1.0 46 4.9 42 16.1 37 9.3
Montenegro 12 5.4 8 9.1 31 11.1 20 22.9 9 13.3
Norway 451 18.3 123 25.6 684 31.3 1179 34.8 245 32.0
Poland 1524 10.3 797 13.4 4442 22.0 2156 33.4 865 23.7
Portugal 521 10.0 340 15.2 621 19.3 893 23.1 325 19.4
Romania 656 8.5 550 12.8 1231 13.7 388 14.7 250 12.9
Russian Federation 2228 4.5 828 5.2 3,425 8.0 2003 12.7 1295 9.1
Serbia 253 5.5 53 3.1 329 5.9 167 9.1 78 6.8
Slovakia 376 16.6 185 18.8 543 27.9 455 40.3 313 30.0
Slovenia 127 11.8 62 18.5 280 26.8 366 39.8 113 28.7
Spain 3678 17.0 1979 27.6 5841 28.4 5021 30.8 2155 26.9
Sweden 623 11.0 133 15.9 542 18.1 1,283 18.9 268 22.2
Switzerland 1091 22.2 301 27.9 1073 32.9 1727 37.6 325 33.8
The Netherlands 1552 13.1 491 22.5 2641 28.7 2825 36.3 862 32.4
Ukraine 124 0.9 5 0.1 209 1.6 38 1.0 82 1.6
United Kingdom 6401 14.3 1349 18.1 7656 24.7 7419 27.9 2049 24.4
Global 40,524 10.2 13,337 12.3 56,558 17.9 59,493 24.4 18,314 18.4
Range 9.4 to 30.0 6.2 to 39.6 6.1 to 48.1 9.0 to 53.5 6.4 to 42.1
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20 February 2016combinations with chemotherapy could also influence the number
of candidates for radiotherapy treatments [17]. In summary, a
decrease in the number of patients due to a reduction in indica-
tions is highly improbable.
The main result of this study is that the absolute number of new
cancer patients with a radiotherapy indication will increase in the
immediate future in almost all European countries, although there
are variations in their relative magnitude between the countries
and regions of Europe. As mentioned, the driver of the predictions
utilized here are the projected population aging and population
growth. Classical drivers of such demographical changes are fertil-
ity, mortality and migration. The latter is the least predictable and
is more prone to short-term changes. However the impact of
migration is usually mainly seen in younger age groups, who have
a relatively low cancer risk. From a global viewpoint, EU countries
exhibit a very moderate short-term increase in the size of the pop-
ulation (0.8% between 2015 and 2020 and 1.2% between 2020 and
2030). The Nordic and some western countries (e.g. France, the
UK), are the only countries to clearly indicate an increase in the
size of the population in the mid- and longer-term projections
[18] until 2050 or later. Eastern European countries show a
decrease in population size in the mid- and longer-term, howeverPlease cite this article in press as: Borras JM et al. How many new cancer patien
Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.02.016the main decrease is predicted beyond 2025 for all these countries,
including the Russian Federation and Ukraine [19].
Aging of the European population, due to the increases in long-
evity and low fertility levels, is a parallel process that explains the
increase in number of cases. One consequence of this process is
that the very old (80 years or older) are the fastest growing popu-
lation age group in Europe. Age and cancer incidence are strongly
associated, hence the aging process has a strong impact on the can-
cer incidence in countries with the highest percentage of older age
groups, such as Germany, Italy or Spain. The main consequence for
radiotherapy as well as for the multidisciplinary management of
this aged patient group is the growing prevalence of patients with
multi-morbidities including cancer, which influences clinical
decision-making. Indeed, one of the most relevant factors that
explains lower than expected indications for radiotherapy is the
presence of comorbidity and old age [20–22]. These clinically-
related factors – coupled with patient preferences – could in part
explain the gap between the optimal and actual use of radiother-
apy observed in different analyses [1,23]. Other factors are more
policy-related and include accessibility problems due to the dis-
tance to radiotherapy departments, lengthy waiting lists, a lack
of resources and/or old therapeutic technologies [1], which arets in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.
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Fig. 3. Top 5: Ranking by absolute number of cancer patients requiring radiotherapy by 2025 (using min OUP).
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20 February 2016all more amenable to health policy efforts. Indeed, differences
between evidence-based indications and clinical practice could
be observed in the relative importance of bladder cancer or lym-
phoma as indication, which is not in line with the actual demand
for radiotherapy in our clinical departments. These discrepancies
may reflect shortcomings of the model or an indication that some
patients with indications for radiotherapy are not being treated
appropriately [24]. These observations should be the target forPlease cite this article in press as: Borras JM et al. How many new cancer patien
Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.02.016health services research in this field in the coming future in order
to refine the projections.
The projections of the new cancer patients are useful to assess
the expected increase in cancer burden and the related impact
for radiotherapy services by country and type of tumor. This anal-
ysis has been done under reasonable and conservative assump-
tions regarding the projections of cancer incidence. Considered
globally, the resources required to cope with the challenge posedts in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.
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20 February 2016by these projections are important, especially as important differ-
ences in the capital resources and staff among European countries
have been documented [25,26], as well as the gap between optimal
and actual use [1]. The fact that such a gulf has been identified in
the majority of European countries and that the need for radiother-
apy has been estimated for optimal utilization, could suggest that a
more conservative target for planning radiotherapy equipment and
staff should be proposed. In this respect, 80% of the optimal
demand may be a reasonable first policy target [27]. Additionally,
the resources required should be invested within the framework
of a national cancer control plan [27,28].
In conclusion, the study has shown that the need for radiother-
apy in Europe on average is expected to increase with 16% from
2012 to 2025. The expected changes in demand varied consider-
ably between countries (range 0–35%). With the already existing
disparity in radiotherapy resources in mind, the data provided here
should act as a leverage point to raise awareness among European
health policy makers of the need for investment in radiotherapy.
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